摘要
目的针对于伊马替尼治疗慢性粒细胞白血病的疗效进行分析。方法选择我院2017 年1 月—2019 年1 月间住院治疗的84 例CML 患者作为研究对象,随机分为观察组和对照组,各42 例。对照组给予常规化疗方案,观察组在此基础上加用伊马替尼,持续接受治疗1 年。分别比较两组患者的临床效果,CCyR、CHR、MMR,免疫功能指标、生活质量评分以及不良反应和耐药性。结果观察组患者的客观缓解率(71.43%)高于对照组(47.62%)(P < 0.05);治疗6 个月和1 年后,观察组的CCyR 显著高于对照组(P < 0.05);治疗后观察组的免疫功能指标和生活质量评分均高于对照组(P < 0.05);不良反应方面,两组间差异无统计学意义(P > 0.05),但观察组伊马替尼原发性耐药率为42.86%,继发性耐药率为23.81%。结论甲磺酸伊马替尼治疗CML具有良好的临床效果,还可有效改善免疫功能和生活质量,安全性良好,但需注意其药物耐药性的发生,严格按照临床指征用药。
Objective To evaluate the efficacy of imatinib in the treatment of chronic myelogenous leukemia. Methods 84 cases of CML patient hospitalized in our hospital from January 2017 to January 2019 were selected as research objects and randomly divided into observation group and control group, with 42 cases each. The control group received conventional chemotherapy, and the observation group received imatinib on top of this, and received continuous treatment for one year. The clinical effects of CCyR, CHR, MMR, immune function indicators, quality of life scores, adverse reactions and drug resistance were compared in the two groups. Results The objective remission rate of the observation group (71.43%) was significantly higher than that of the control group (47.62%)(P<0.05).After 6 months and one year of treatment, CCyR in the observation group was significantly higher than that in the control group (P<0.05).After treatment, the immune function index and life quality score of the observation group were significantly better than those of the control group (P<0.05).In terms of adverse reactions, there was no significant difference between the two groups (P>0.05), but the primary drug resistance rate of imatinib in the observation group was 42.86%, and the secondary drug resistance rate was 23.81%. Conclusion Imatinib mesylate has a good clinical effect in treating CML, and can effectively improve immune function and quality of life, with good safety. However, it is necessary to pay attention to the occurrence of drug resistance, and use drugs according to clinical instructions.
作者
邢丰
冯国安
XING Feng;FENG Guoan(Department of Hematology and Oncology,Dafeng People's Hospital, Yancheng Jiangsu 224100, China)
出处
《中国继续医学教育》
2019年第30期147-150,共4页
China Continuing Medical Education
关键词
伊马替尼
慢性粒细胞白血病(CML)
疗效评估
耐药性
客观缓解
免疫功能
imatinib
chronic myelogenous leukemia (CML)
efficacy assessment
drug resistance
objective response
immunologic function
